The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
AABB to Present on CGT Quality Gaps at Meeting on the Mesa
September 08, 2026
AABB Accepting Lightning Talk Proposals for Cord Blood Connect 2026 Through Tuesday
September 02, 2026
New CTMC Review Highlights Key Advances in Transfusion Medicine and Biotherapies From 2025
September 01, 2026